A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic-Triple-Negative Breast Cancer
Protocol Chair: Leisha A. Emens, MD, PhD
Protocol Officer: Samuel Jacobs, MD
Primary Objective: To establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer.
Patient Population: Metastatic triple-negative breast cancer
Target Accrual: 29 patients
Status: Recruiting participants
ClinicalTrials.gov Identifier: NCT04024800
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402